* Says decided goals of Qnexa study with FDA
* Plans to resubmit Qnexa marketing approval in Q4 as lmtd indication
* Q1 loss per shr $0.12 vs est $0.15
* Shares up 6 pct after-market (Follows alerts)
May 2 (Reuters) - Drugmaker Vivus Inc said it plans to resubmit its application to market its obesity drug in the fourth quarter as a limited indication, sending its shares up 6 percent after the bell.
The company also said it met with the Food and Drug Administration on April 14 and agreed on the goals of a feasibility study on Qnexa.
In January, the FDA asked Vivus to assess the feasibility of analyzing existing databases to determine the historical incidence of oral cleft — commonly known as cleft lip — in offspring of women treated with topiramate. [ID:nN21201141]
Vivus’s Qnexa combines topiramate, which has been used for seizures and migraines, with another drug, phentermine.
The resubmission of marketing approval for Qnexa for a limited indication would include only men and women of non-child bearing potential.
Vivus also narrowed its quarterly loss and beat market estimates, as it reduced research and development spending on its drugs.
Vivus reported a first-quarter net loss of $9.9 million, or 12 cents per share, compared with a net loss of $18.8 million, or 23 cents per share, a year earlier.
Analysts on an average were expecting a loss of 15 cents per share, according to Thomson Reuters I/B/E/S.
Shares of the Mountain View, California-based company were trading up 6 percent at $8.25 in after-market trade on Monday. They closed at $7.80 on Nasdaq. (Reporting by Aniket Basu in Bangalore; Editing by Jarshad Kakkrakandy)